Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trial

Clinical Pharmacology in Drug Development

Volumn 3, Issue 1, 2014, Pages 18-24

  Kosoglou, Teddy ^a   Hunt, Thomas L ^b   Xuan, Fengjuan ^a   Kumar, Bharath ^a   Statkevich, Paul ^a   Hanson, Mary E ^a   Cutler, David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Pharmaceutical Product Development   (United States)

Author keywords

Cardiac safety; PAR 1; QT QTc prolongation; Thrombin receptor antagonist; Vorapaxar

Indexed keywords

MOXIFLOXACIN; PLACEBO; VORAPAXAR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEPHAROSPASM; BLURRED VISION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HOLTER MONITORING; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; MOOD DISORDER; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; URTICARIA;

EID: 84892463941     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.49     Document Type: Article

References (9)

1. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008; 51:3061-3064.
2. Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003; 304:855-861.
3. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012; 366:20-33.
4. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366:1404-1413.
5. International Conference for Harmonization E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Step. 4: 1-14. 2005. London, England, European Medicines Agency.
6. Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012; 68:249-258.
7. Statkevich P, Kosoglou T, Kumar B. et al. Pharmacokinetics of vorapaxar and its metabolite SCH 2046273 (M20) following oral administration in healthy Chinese and US subjects. Clin Pharmacol Ther. 2012; 91:S54, Abstract PII-9.
8. Kosoglou T, Reyderman L, Kasserra C, et al. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2012; 68:291-300.
9. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009; 373:919-928.